All In MedTech

FDA Clearance Tracker · K242706

Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio

A 510(k) clearance means FDA found the device substantially equivalent to one already on the market. It is not an approval, and it is not a finding that the device works better than others.

Last checked: Nov 19, 2026Latest source record: May 16, 2025 (this decision)Source: openFDAMethods & limitations

510(k)First of its product codeBreakthrough

Decided

May 16, 2025

Substantially Equivalent

Time to decision

249 days

Received Sep 9, 2024. Calendar days, including time FDA spent waiting on the applicant.

Pathway

510(k)

Traditional

Device class

Class II

The decision

FDA number
K242706
Device name
Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio
Applicant location
Malvern, PA
Received
Sep 9, 2024
Decided
May 16, 2025
Decision
Substantially Equivalent
Submission type
Traditional

Device type

Device class
Class II
Regulation
21 CFR 866.5840

Every decision under product code SET

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • This is the earliest decision in FDA's data under product code SET (Immunoassay Blood Test For Amyloid Pathology Assessment).
  • It is on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026).

Source documents

The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.

Other decisions for Fujirebio Diagnostics,Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.